What type of study is this?

This is a Systematic Review study.

What question did this study set out to answer?

To assess the incidence and types of secondary malignancies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Systematic review reveals secondary malignancy incidence in chronic myeloid leukemia patients treated with TKIs, suggesting a need for monitoring.

To assess the incidence and types of secondary malignancies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Conducted a systematic review following PRISMA guidelines.
Performed literature search across PubMed, Embase, Medline, and Web of Science.
Included studies reporting on secondary malignancies in adults with chronic-phase CML treated with TKIs; excluded those with advanced CML or concomitant chemotherapy.
Identified 14 studies including 42,781 chronic-phase CML patients treated with TKIs.
Reported secondary malignancy incidence ranged from 3.1% to 7.5% in various cohorts.
Common secondary malignancies included prostate, colorectal, and lung cancers, along with hematologic malignancies like non-Hodgkin lymphoma.

Benkhadra et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Systematic review reveals secondary malignancy incidence in chronic myeloid leukemia patients treated with TKIs, suggesting a need for monitoring.

To assess the incidence and types of secondary malignancies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Conducted a systematic review following PRISMA guidelines.
Performed literature search across PubMed, Embase, Medline, and Web of Science.
Included studies reporting on secondary malignancies in adults with chronic-phase CML treated with TKIs; excluded those with advanced CML or concomitant chemotherapy.
Identified 14 studies including 42,781 chronic-phase CML patients treated with TKIs.
Reported secondary malignancy incidence ranged from 3.1% to 7.5% in various cohorts.
Common secondary malignancies included prostate, colorectal, and lung cancers, along with hematologic malignancies like non-Hodgkin lymphoma.

Benkhadra et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark